Archives

  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br The Cancer Genome Atlas Data

    2022-05-07


    The Cancer Genome Atlas Data and cBioPortal
    The Cancer Genome Atlas had both sequencing and pathological data on 30 different cancers.45 The breast invasive carcinoma (The Cancer Genome Atlas, Provisional) dataset, including data from 1,107 cases with pathology reports, was selected for further analyses of E2Fs using cBioPortal (http://www.cbioportal.org/index.do? session_id= 5b4c1773498eb8b3d566f7b8). The genomic profiles included mutations, putative copy number alterations (CNAs) from genomic identification of significant targets in cancer (GISTIC), mRNA expression Z scores (RNA-seq v.2 RSEM), and protein expression Z scores (reverse phase protein array [RPPA]). Co-expression and network were calculated according to the cBioPortal’s online instructions.
    Immunohistochemistry
    3-mm tumor sections were incubated with commercial rabbit poly-clonal Ko 143 against E2F1, E2F2, E2F3, E2F4, E2F5, E2F6, E2F7, and E2F8 (all from Santa Cruz Biotechnology) at 1/100 dilution overnight at 4 C. Then, the sections were conjugated with horse-radish peroxidase (HRP) antibody (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature for 2 h, then covered by 3, 3-diaminobenzidine (DAB) (Vector Laboratories, Bur-lingame, CA), and slides were mounted with Vectashield mounting medium (Vector Laboratories). Subsequently, all fields were observed under light microscopy (Olympus 600 auto-biochemical analyzer, Tokyo, Japan). Control experiments without primary antibody demonstrated that the signals observed were specific.
    AUTHOR CONTRIBUTIONS
    CONFLICTS OF INTEREST
    The authors declare no competing interests.
    ACKNOWLEDGMENTS
    This study was funded by the National Natural Science Foundation of China (81802285), the National Postdoctoral Program for Innovative Talents (BX201700178), the China Postdoctoral Science Foundation (2017M620340), the Fundamental Research Funds for the Central Universities (2015305020202 and 2042018kf0025), the Health Com-mission of Hubei Province scientific research project (WJ2019Q039), the Hubei Province Key Laboratory of Occupational Hazard Identifi-cation and Control (OHIC2017Y02), the Wuhan University Startup Funds, and the Independent Research Funds of School of Health Sci-ences at Wuhan University to C.-C.S. It was also supported by the
    Health Commission of Wuhan City Scientific Research Project (WG18Q01) to S.-J.L.
    REFERENCES
    5. Shackney, S.E., Chowdhury, S.A., and Schwartz, R. (2014). A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers. Cancer Inform. 13 (Suppl 5 ), 89–100.
    12. Johnston, S.R. (2006). Clinical efforts to combine endocrine agents with targeted ther-apies against epidermal growth factor receptor/human epidermal growth factor re-ceptor 2 and mammalian target of rapamycin in breast cancer. Clin. Cancer Res. 12, 1061s–1068s.
    13. Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., and Senkus, E.; ESMO Guidelines Working Group (2012). Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl 7 ), vii11–vii19.
    www.moleculartherapy.org
    44. Gy orffy, B., Surowiak, P., Budczies, J., and Lánczky, A. (2013). Online survival anal-ysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE 8, e82241.
    Contents lists available at ScienceDirect
    International Journal of Biochemistry
    and Cell Biology
    journal homepage: www.elsevier.com/locate/biocel
    Comprehensive circular RNA expression profiles and the tumor-suppressive T function of circHIPK3 in ovarian cancer
    Fang Tenga,1, Juan Xua,1, Min Zhangb, Siyu Liua, Yuanyuan Gua, Mi Zhanga, Xusu Wanga, Jing Nic, Bing Qianc, Rong Shena, , Xuemei Jiaa,
    a Department of Gynecology, Women’s Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital), Nanjing 210004, China
    b Gannan Medical University, Ganzhou 341000, China
    c Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210094, China
    Keywords:
    Circular RNA
    Ovarian cancer
    circHIPK3
    Tumor-suppressive function 
    Background: With the development of next-generation sequencing (NGS), thousands of circular RNAs (circRNAs) have been found. Many circRNAs have been verified to play vital roles in carcinogenesis. However, whether circRNAs engage in the development and progression of ovarian cancer remains to be clarified.